Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia

J Med Chem. 2014 May 22;57(10):3912-23. doi: 10.1021/jm4019299.

Martha J Kelly ¹, Sherrie Pietranico-Cole, J Douglas Larigan, Nancy-Ellen Haynes, Charles H Reynolds, Nathan Scott, John Vermeulen, Mark Dvorozniak, Karin Conde-Knape, Kuo-Sen Huang, Sung-Sau So, Kshitij Thakkar, Yimin Qian, Bruce Banner, Frank Mennona, Sara Danzi, Irwin Klein, Rebecca Taub, Jefferson Tilley

Affiliations

Affiliation

1 Madrigal Pharmaceuticals, Inc. , Fort Washington, Pennsylvania 19034, United States.

PMID: 24712661 DOI: 10.1021/jm4019299

Abstract

The beneficial effects of thyroid hormone (TH) on lipid levels are primarily due to its action at the Thyroid Hormone Receptor β (THR-β) in the liver, while adverse effects, including cardiac effects, are mediated by Thyroid Hormone Receptor α (THR-α). A pyridazinone series has been identified that is significantly more THR-β selective than earlier analogues. Optimization of this series by the addition of a cyanoazauracil substituent improved both the potency and selectivity and led to MGL-3196 (53), which is 28-fold selective for THR-β over THR-α in a functional assay. Compound 53 showed outstanding safety in a rat heart model and was efficacious in a preclinical model at doses that showed no impact on the central thyroid axis. In reported studies in healthy volunteers, 53 exhibited an excellent safety profile and decreased LDL Cholesterol (LDL-C) and triglycerides (TG) at once daily oral doses of 50 mg or higher given for 2 weeks.

Products

Cat. No.

Product Name

Description

Target

Research Area
HY-12216

Resmetirom

99.90%, THR-β Agonist

Thyroid Hormone Receptor

Endocrinology; Cardiovascular Disease

Name
Email *

	Sorry, but the email address you supplied was invalid.